Skyrizi vs Remicade for Crohn's Disease: Which Is Better?

Skyrizi and Remicade represent two very different eras of Crohn's biologic therapy. Remicade (infliximab) has been the anti-TNF workhorse since its approval in the late 1990s. Skyrizi (risankizumab) is a newer IL-23 p19-selective biologic that gained Crohn's approval in 2022 and has quickly gained market share. Patients often compare these drugs when starting biologic therapy for the first time or when weighing alternatives after Remicade has lost effect. This guide walks through the evidence for the skyrizi vs remicade crohn's decision.

Mechanism: IL-23 vs Anti-TNF

Remicade (infliximab) is a chimeric monoclonal antibody that binds TNF-alpha, neutralizing a cytokine that drives inflammation throughout the body and in the gut. Skyrizi (risankizumab) binds the p19 subunit of interleukin-23, selectively blocking IL-23 signaling. IL-23 is a central driver of the Th17 pathway in Crohn's inflammation, while TNF-alpha is more widely distributed. The risankizumab vs infliximab distinction matters because mechanism drives both efficacy and safety. Anti-TNF blockade produces faster systemic anti-inflammatory effects and covers extraintestinal manifestations. IL-23 targeting produces a cleaner safety profile with strong endoscopic outcomes.

Efficacy in Crohn's Disease

Remicade's Crohn's efficacy rests on the ACCENT I and ACCENT II trials, which established infliximab as a standard first-line biologic. Skyrizi's ADVANCE and MOTIVATE induction trials, along with the FORTIFY maintenance trial, established its efficacy across biologic-naive and anti-TNF experienced populations. No head-to-head trial has directly compared Skyrizi with Remicade in Crohn's. Indirect comparisons from network meta-analyses suggest similar clinical remission rates, with Remicade often ranking slightly higher on induction clinical remission in anti-TNF-naive patients and Skyrizi showing strong endoscopic outcomes across both populations. In patients who have lost response to Remicade, Skyrizi produces meaningful remission rates, particularly if antidrug antibody formation has been the failure mechanism.

Onset of Action

Remicade works fast. Many patients report symptom improvement within the first two weeks of induction, with full response evident by week 8. Skyrizi's onset is slightly slower, with meaningful improvement by week 4 and full response typically evident by week 12. For Crohn's patients with severe, active disease who need rapid symptom control, Remicade's faster onset sometimes matters clinically. For patients in a less acute state or those evaluating long-term maintenance, both drugs offer reasonable timelines.

Safety and Infection Risk

Remicade carries the anti-TNF class risks of serious infections, reactivation of latent TB or hepatitis B, and a small increase in lymphoma risk. Long-term IBD registry data shows higher hospitalization rates for serious infection on infliximab compared with IL-23 pathway biologics. Skyrizi's safety profile has been favorable across its Crohn's and psoriasis programs. In ADVANCE and MOTIVATE, serious adverse events were comparable to placebo rates, and long-term extension data shows continued good tolerability. Both drugs require TB and hepatitis B screening before starting. For Crohn's patients with infection concerns, cancer history, or other risk factors for immunosuppression complications, Skyrizi's narrower mechanism often looks more favorable.

Dosing and Administration

Remicade uses three IV induction doses at weeks 0, 2, and 6, followed by maintenance infusions every 8 weeks at 5 mg/kg, with dose escalation to 10 mg/kg available if response wanes, per Janssen's Remicade information. Skyrizi for Crohn's uses IV induction at weeks 0, 4, and 8 (600 mg per infusion), then transitions to 360 mg subcutaneous every 8 weeks. After induction, Skyrizi eliminates infusion center visits entirely. Remicade requires lifelong infusions unless the patient switches drugs. For crohn's second-line biologic decisions where convenience is a factor, Skyrizi's SC maintenance is a meaningful practical advantage over Remicade's continued IV schedule.

Switching From Remicade to Skyrizi

Crohn's patients who lose response to Remicade frequently consider Skyrizi as a next step. The mechanism change is supported by trial data. MOTIVATE specifically enrolled anti-TNF experienced patients and demonstrated meaningful endoscopic response and clinical remission on Skyrizi. Compared with cycling to a second anti-TNF, which typically delivers lower response rates than switching classes, a mechanism change to IL-23 blockade is often preferred after Remicade failure. The skyrizi after remicade transition generally does not require a washout period, though timing depends on individual patient factors and any residual Remicade levels or antibodies.

Cost and Access

Remicade faces extensive biosimilar competition. Inflectra (infliximab-dyyb) and Renflexis (infliximab-abda) are widely available and often preferred on insurance formularies, which can lower acquisition costs substantially. Skyrizi has no biosimilar and is priced as a branded biologic. For Crohn's patients where insurance favors a low-cost infliximab biosimilar, Remicade (or its biosimilar) may be the most accessible option. For patients whose plans cover Skyrizi and prioritize the IL-23 mechanism or SC maintenance convenience, the cost gap is often bridged by manufacturer copay assistance programs for commercially insured patients.

Choosing With Your GI

For a Crohn's patient deciding between Skyrizi and Remicade, both drugs deliver meaningful response in biologic-naive patients. Remicade tends to win on induction speed, dose escalation flexibility, and biosimilar cost savings. Skyrizi tends to win on long-term safety, SC maintenance convenience, and efficacy in anti-TNF experienced patients. Ask your GI how response will be measured after induction, what to do if symptoms persist, and whether therapeutic drug monitoring will be used alongside your biologic. A log of stool frequency, urgency, abdominal pain, and any new extraintestinal symptoms between visits gives your care team the data to recognize early loss of response before a full flare develops.